Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
Provided By PR Newswire
Last update: Mar 4, 2025
2024 highlights include expanded product labeling, key FDA designations and new study publications
Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval
Read more at prnewswire.comNASDAQ:CPIX (11/7/2025, 8:00:01 PM)
2.13
-0.06 (-2.74%)
Find more stocks in the Stock Screener
